Providencia stuartii is frequently associated with nosocomial outbreaks and displays intrinsic resistance to many commonly used antimicrobials. We report here the draft genome sequence of a P. stuartii strain carrying acquired resistance genes conferring panresistance to cephalosporins (bla and bla VEB-1 ), carbapenems (bla VIM-1 ), and aminoglycosides (rmtB) involved in an outbreak in Greek hospitals.
P rovidencia stuartii has emerged as an important nosocomial pathogen responsible for urinary tract infections in patients with indwelling urinary catheters, hospitalacquired pneumonia, bloodstream infections, and sepsis (1), with significant impact on patient morbidity, mortality, treatment, and management costs (2) .
P. stuartii isolate PS71 was recovered in 2013 from the bloodstream of a patient during a cluster of P. stuartii infections in a critical care unit in a tertiary-care hospital in Athens, Greece (3). This outbreak-associated strain exhibited resistance to cephalosporins (first, second, third, and fourth generation), ␤-lactam-inhibitor combinations (amoxicillin-clavulanate and piperacillin-tazobactam), carbapenems (ertapenem and imipenem), aminoglycosides, fosfomycin, polymyxins (colistin and polymyxin B), quinolones, and tigecycline (3).
Genomic DNA was extracted and subjected to whole-genome sequencing with the Illumina MiSeq platform (Illumina, Inc., San Diego, CA), producing 2 ϫ 250-bp pairedend reads, generating a total of 843,412 reads with a 475 bp average length. The Trimmomatic algorithm (version 0.36) (4) was used to trim all the generated reads and their quality assessed with in-house scripts using BedTools (version 2.25.0) (5), BWAmem (version 2) (6), and SAMtools (version 1.3.1) (7) algorithms. High-quality filtered reads were subsequently assembled de novo using SPAdes algorithm (version 3. Provisional annotation carried out using the Prokka algorithm (version 1.11) (9) identified at least 4,026 coding sequences (CDSs), including 76 tRNAs and eight rRNAs. The assembled genome was used to predict the presence of acquired antibiotic resistance genes using ResFinder (10) and confirmed the presence of 24 genes conferring resistance to aminoglycosides [aadA1, aadA2, aadB, aac(6=)-Ia, aph(3=)-Ia, strA, strB, and rmtB], ␤-lactams (bla TEM-1b , bla OXA-10 , bla SHV-5 , bla VEB-1 , and bla VIM-1 ), macrolides, lincosamides, and streptogramin B [mph(A)] and phenicols (cmlA1 and catA3), rifampin (arr-2), sulfonamides (sul1 and sul2), tetracyclines [tet(A), tet(B), and tet(G)], and trimethoprim (dfrA1 and dfrA12) . The presence of multidrug efflux pump-mediated resis-tance mechanisms was also inferred from the genome (i.e., acrB, acrR, cmeB, mtrF, mfs, macA, macB, and tolC), as well as resistance to toxic compounds, including arsenic (arsA, arsB, arsC, arsD, and arsR), cadmium, cobalt and zinc (czcB, czcD, trcD, and trMer), and mercury (merA, merC, merD, merE, and merR). PlasmidFinder (11) indicated that PS71 contains plasmids with ColE, A/C, and R replicon types, with the latter located on a multireplicon plasmid (3) .
There are increasing reports of multiresistant strains of Providencia in the Mediterranean, and enhanced surveillance is needed to identify and track the epidemiology of resistant strains, their impact on human health, and the molecular epidemiology. This is the first draft genome sequence of such a multiresistant P. stuartii strain associated with a nosocomial outbreak in Greece. Accession number(s). The draft genome sequence of P. stuartii PS71 has been deposited in the DDBJ/EMBL/GenBank databases under the accession number MSAA00000000. The version described in this paper is the first version, MSAA01000000.
